Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-11-30

Study Completion Date

2013-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, double blind controlled trial in which patients with esophagic variceal bleeding treated with standard therapy (endoscopic variceal ligation(EVL) + B-blockers), will be randomized to receive statins or placebo. They will be followed up during 12 months to determinate whether statins are effective in prevention of variceal bleeding recurrence and evaluate patient survival.

Randomization will be stratified according to the degree of hepatic insufficiency, assessed by the Child-Pugh classifications (A,B or C).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Simvastatin in the Treatment of Portal Hypertension

NCT00594191

Cirrhosis Portal Hypertension

COMPLETED PHASE2

Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis

NCT03654053

Cirrhosis

ACTIVE_NOT_RECRUITING PHASE3

Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis

NCT01282398

Portal Hypertension. Liver Cirrhosis

UNKNOWN PHASE4

Simvastatin Plus Rifaximin in Decompensated Cirrhosis

NCT03150459

Cirrhoses, Liver

COMPLETED PHASE2

Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development

NCT03780673

Liver Cirrhoses

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A mayor cause of cirrhosis-related morbility and mortality is the development of variceal hemorrhage, a direct consequence of portal hypertension. In addition, survivors of an episode of active bleeding have a 70 % risk of recurrent hemorrhage within two years of the bleeding episode and the highest risk it is situated in the first six weeks after the hemorrhage episode.

The recommended treatment in AASLD guidelines is the combination of non selective Betablockers with endoscopic treatment with EVL, with high recurrence (30% in 2 years).

The hypothesis of this study is that statins are candidates for improving portal hypertension treatment in patients with cirrhosis, improving vascular function as well as preventing venous thrombotic events.

Patients with liver cirrhosis and variceal bleeding with standard treatment will be stratified and after randomized to undergo either statins (20 mg for 15 days, and after 40 mg/day) or placebo. They will be followed up for 12 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cirrhosis Hypertension, Portal Bleeding Esophageal Varices Portal Vein Thrombosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard therapy + Simvastatin

* Standard therapy: Endoscopic variceal ligation (EVL)+ B Blockers (Propanolol titrated until achieve maximum tolerated dose)
* Simvastatin (20 mg for 15 days and after 40 mg/day until the end of the study)

Group Type EXPERIMENTAL

Simvastatin

Intervention Type DRUG

Simvastatin 20 mg for 15 days, then 40 mg until the end of the study.

Standard therapy + placebo

* Standard therapy: Endoscopic variceal ligation (EVL)+ B Blockers (Propanolol titrated maximum tolerated dose).
* Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Simvastatin placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Simvastatin

Simvastatin 20 mg for 15 days, then 40 mg until the end of the study.

Intervention Type DRUG

Placebo

Simvastatin placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Simvastatina Simvastatina Ratiopharm

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients between 18 and 80 years old.
* Clinical criteria and/or analytical, ultrasound and/or liver biopsy consistent with the diagnosis of liver cirrhosis.
* Hematemesis or melenas within 7 days prior to study inclusion.
* Variceal bleeding. Endoscopic diagnosis:

* Active variceal bleeding.
* Clot or platelet cluster or,
* Esophageal varices associated to red blood in esophagogastric lumen in the absence of other sources of bleeding.
* Patients with standard treatment for prevention of recurrence of variceal bleeding (EVL+B Blockers,Propanolol).
* Women of childbearing age should have a urine pregnancy test negative for 7 days before commencement of treatment and postmenopausal women must have amenorrhea for at least 12 months to be considered not fertile. Potential childbearing women and men must commit to use adequate contraception prior to joining the study and during it.
* Written informed consent to participate in the study.

Exclusion Criteria

* Pregnancy or lactation
* Presence multiple hepatocellular carcinoma or only diameter\> 5 cm.
* Renal failure ( Creatinine \> 2 mg/dl)
* Advanced liver disfunction (Child Pugh \> 13 points)
* Contraindication for statins.
* Patients HIV treated with antiretroviral therapy.
* Pre-treatment with portosystemic shunt ( surgical or percutaneous).
* Bleeding due to gastric varices.
* Patients with total portal vein thrombosis or portal cavernomatosis.
* Patients previously treated with endoscopic variceal ligation and B- Blockers (before index episode).
* Patients previously treated with statins ( one month before the study).

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No